Menu Search
Equities

Fonar Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FOAA:FRA

Fonar Corp

Actions
  • Price (EUR)15.60
  • Today's Change0.10 / 0.65%
  • Shares traded1.51k
  • 1 Year change+4.00%
  • Beta0.9884
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

FONAR Corporation is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (MRI) for the detection and diagnosis of human diseases. The Company conducts its business in two segments: medical equipment and physician management and diagnostic services. Its medical equipment segment is conducted directly through the Company. Its physician management and diagnostic services segment is conducted through its subsidiary, Health Management Corporation of America (HMCA). Its signature product is the FONAR UPRIGHT Multi-Position MRI (STAND-UP MRI). HMCA provides management services, administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, hiring, maintenance service, and clerical and other non-medical personnel to medical providers engaged in diagnostic imaging. HMCA owns and operates six diagnostic imaging facilities in Florida.

  • Revenue in USD (TTM)105.43m
  • Net income in USD6.99m
  • Incorporated1978
  • Employees535.00
  • Location
    Fonar Corp110 Marcus DrMELVILLE 11747-4228United StatesUSA
  • Phone+1 (631) 694-2929
  • Fax+1 (631) 753-5150
  • Websitehttps://www.fonar.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.